Whole-Body MRI: Myeloma, Metastases & Screening
Imaging head-to-thighs in one sitting, without radiation, to find and track disease across the whole skeleton and beyond.
How it works
Whole-body MRI stitches together multiple stations, typically combining anatomical sequences with diffusion-weighted imaging (DWI). DWI highlights cellular disease against normal marrow, and inverted greyscale maps give a PET-like overview of active lesions, all without ionising radiation.
Main uses
- Multiple myeloma: now a recommended tool for staging and detecting focal lesions earlier than skeletal survey.
- Metastatic bone disease: staging and treatment-response assessment, e.g. in prostate and breast cancer.
- Cancer-predisposition surveillance: screening in syndromes such as Li-Fraumeni.
- Selected screening: increasingly offered privately, with important caveats about incidental findings.
The screening caveat
As a general “wellness” screen in asymptomatic people, WB-MRI frequently finds incidentalomas: benign findings that trigger anxiety, further tests and procedures without clear survival benefit. Its evidence base is strongest in defined high-risk groups and specific cancers, not the worried well.
Sources
- Messiou C et al. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma (MY-RADS). Radiology 2019;291:5–13.
Educational summary for clinicians; screening use is debated and should follow evidence-based guidance. Not medical advice.